Polymeric micelle particle comprising anionic drugs and method of preparing the same

1. A polymeric micelle particle, comprising:

an anionic drug as an active ingredient;

a lipid comprising a cationic lipid; and

an amphiphilic block copolymer,

wherein the anionic drug forms a complex with the cationic lipid by electrostatic interactions, and the complex of the anionic drug and the cationic lipid is entrapped in the core-shell type polymeric micelle structure of the amphiphilic block copolymer which is an A-B type di-block copolymer comprising a hydrophilic A block forming the shell and a hydrophobic B block forming the core,

wherein the hydrophilic A block is one or more selected from the group consisting of polyalkyleneglycol, polyvinyl alcohol, polyvinyl pyrrolidone, polyacrylamide, and a derivative thereof, and the hydrophobic B block is one or more selected from the group consisting of polyester, polyanhydride, polyamino acid, polyorthoester, and polyphosphazine, and

wherein the particle is free from a polyethyleneglycol (PEG)-lipid conjugate, and a polyamide (ATTA)-lipid conjugate,

wherein the hydrophobic B block has a number average molecular weight of 1,000 to 50,000 Dalton,

wherein a weight ratio of (a) the complex of the anionic drug and the cationic lipid to (b) the amphiphilic block copolymer ((a)/(b)×100) is 0.01 to 50 wt %.

2. The polymeric micelle particle of claim 1 , wherein an amount of the amphiphilic block copolymer ranges from 40 to 98% by weight based on a total weight of the particle.

3. The polymeric micelle particle of claim 1 , wherein an amount of the cationic lipid ranges from 0.1 to 15% by weight based on a total weight of the particle.

4. The polymeric micelle particle of claim 1 , wherein a weight ratio of the amphiphilic block copolymer to the lipid ranges from 1.5 to 20.

5. The polymeric micelle particle of claim 1 , wherein the anionic drug is nucleic acid.

6. The polymeric micelle particle of claim 5 , wherein the nucleic acid is one or more selected from the group consisting of RNA, DNA, siRNA (short interfering RNA), aptamer, antisense ODN (oligodeoxynucleotide), antisense RNA, ribozyme, and DNAzyme.

7. The polymeric micelle particle of claim 5 , wherein the nucleic acid has at least one end modified with one or more selected from the group consisting of cholesterol, tocopherol, and C10-C24 fatty acid.

8. The polymeric micelle particle of claim 1 , wherein the amphiphilic block copolymer has the hydrophobic B block whose hydroxyl end group is modified with one or more selected from the group consisting of cholesterol, tocopherol, and C10-C24 fatty acid.

9. The polymeric micelle particle of claim 1 , wherein the cationic lipid is one or more selected from the group consisting of N,N-dioleyl-N,N-dimethylammoniumchloride (DODAC), N,N-distearyl-N,N-dimethylammoniumbromide (DDAB), N-(1-(2,3-dioleoyloxy)propyl-N,N,N-trimethylammoniumchloride (DOTAP), N,N-dimethyl-(2,3-dioleoyloxy)propylamine (DODMA), 1,2-diacyl-3-trimethylammonium-propane (TAP), 1,2-diacyl-3-dimethylammonium-propane (DAP), 3β-[N—(N′,N′,N′-trimethylaminoethane)carbamoyl]cholesterol (TC-cholesterol), 3 β[N—(N′,N′-dimethylaminoethane)carbamoyl]cholesterol (DC-cholesterol), 3β[N—(N′-monomethylaminoethane)carbamoyl]cholesterol (MC-cholesterol), 3β[N-(aminoethane)carbamoyl]cholesterol (AC-cholesterol), cholesteryloxypropane-1-amine (COPA), N—(N′-aminoethane)carbamoylpropanoic tocopherol (AC-tocopherol), and N—(N′-methylaminoethane)carbamoylpropanoic tocopherol (MC-tocopherol).

10. The polymeric micelle particle of claim 1 , wherein the ratio of quantities of electric charges of the cationic lipid (N) and the anionic drug (P) (N/P) is 0.1 to 128.

11. The polymeric micelle particle of claim 1 , wherein the hydrophilic A block is one or more selected from the group consisting of monomethoxy polyethylene glycol, monoacetoxy polyethylene glycol, polyethylene glycol, a copolymer of polyethylene and propylene glycol, and polyvinyl pyrrolidone, and the hydrophobic B block is one or more selected from the group consisting of polylactide, polyglycolide, polycaprolactone, polydioxane-2-one, a copolymer of polylactide and glycolide, a copolymer of polylactide and polydioxane-2-one, a copolymer of polylactide and polycaprolactone, and a copolymer of polyglycolide and polycaprolactone.

12. The polymeric micelle particle of claim 11 , wherein the hydrophilic A block is monomethoxy polyethylene glycol, and the hydrophobic B block is polylactide.

13. The polymeric micelle particle of claim 1 , wherein the hydrophilic A block has a number average molecular weight of 200 to 50,000 Dalton.

14. The polymeric micelle particle of claim 1 , wherein the lipid further comprises at least one fusogenic lipid selected from the group consisting of phospholipid, cholesterol, and tocopherol.

15. The polymeric micelle particle of claim 14 , wherein the phospholipid is one or more selected from the group consisting of phosphatidylethanolamine (PE), phosphatidylcholine (PC), and phosphatidic acid.

16. The polymeric micelle particle of claim 14 , wherein the fusogenic lipid is one or more selected from the group consisting of dilauroyl phosphatidylethanolamine, dimyristoyl phosphatidylethanolamine, dipalmitoyl phosphatidylethanolamine, distearoyl phosphatidylethanolamine, dioleoyl phosphatidylethanolamine, dilinoleoyl phosphatidylethanolamine, 1-palmitoyl-2-oleoyl phosphatidylethanolamine, 1,2-diphytanoyl-3-sn-phosphatidylethanolamine, dilauroyl phosphatidylcholine, dimyristoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, distearoyl phosphatidylcholine, dioleoyl phosphatidylcholine, dilinoleoyl phosphatidylcholine, 1-palmitoyl-2-oleoyl phosphatidylcholine, 1,2-diphytanoyl-3-sn-phosphatidylcholine, dilauroyl phosphatidic acid, dimyristoyl phosphatidic acid, dipalmitoyl phosphatidic acid, distearoyl phosphatidic acid, dioleoyl phosphatidic acid, dilinoleoyl phosphatidic acid, 1-palmitoyl-2-oleoyl phosphatidic acid, 1,2-diphytanoyl-3-sn-phosphatidic acid, cholesterol, and tocopherol.